Skills invoked this turn: Skill_1, Skill_2, Skill_3



==================================================
TURN 1
==================================================

--- RAW THINKING ---
Alright, here's the plan. I'm about to dive into auditing the "Anti Cancer Medicines" category. This isn't just about tweaking some fields; it's about ensuring data integrity for high-stakes pharmaceuticals. Precision is paramount.

My first step is to *plan*. I need to thoroughly understand the current spec set and the data I have.

*   **Phase 1: PLAN** First, I'm defining the scope. Anti-cancer medicines are highly regulated and valuable, so the specs must be spot-on. I'll need to focus on API, dosage, and manufacturer, as these are the crucial identifiers.

*   **Formulate Questions:** My approach will be driven by questions, not assumptions. I'll be questioning the current spec set by looking at the data. I'm starting by comparing the current spec set to the call data, fill rate, and buyer search data and looking for any potential duplicate specs (ex: Brand Name and Brand; composition and generic name). Next I'll analyze overlapping spec sets (e.g. "Packaging Size" versus "Pack Size" and others). Missing attributes such as "Shelf Life" are investigated as well. I'll also check if the existing tertiary spec "Usage / Application" is useful and if there are better spec names (e.g. "Dosage Form" versus "Form"). I'll flag any data weirdness that pops up.

*   **Identify Priority Areas:** Based on these questions, I'll pinpoint the biggest issues. Consolidating duplicates is the first priority, followed by adding critical specs like "Shelf Life". Useless ones like "Usage / Application" will be scrutinized for removal. The accuracy of existing primary specs will be reviewed as well as the need for secondary specs.

*   **Identify Consolidation Candidates:** I'll map out how I'll consolidate these duplicates. For example, "Brand" and "Brand Name" will likely become "Brand Name", while all the packaging related attributes may consolidate into a quantity and packaging form. Specs like "Treatment" and "Indication" will be considered for consolidation.

*   **Plan the Tool Sequence:** I will use the skills available to gather evidence. I'll start with the investigator skills to get a broad view, followed by missing spec analysis, and then refinement/validation steps.

*   **Define Constraints:** For this category, I need precision. Long lists of options are fine for some specs (like composition), but others should remain concise. I'll aim for only the essential attributes as primary specs.

*   **Phase 2: INVESTIGATE:** Okay, with the plan set, it's time to put it into action. I'll start by processing the raw data using the investigator skills, paying close attention to the evidence. I'll generate the tags for my first turn, which will summarize all of the data that the skills provided.

(Self-Correction during planning): I realized my initial thinking was too focused on a "fix it" mentality. Now I'm framing everything as questions, using the data to make an argument. This avoids bias. I also noted that the "Custom Spec Data" included both "Manufacturer" and "Marketer". This has potential as a consolidation point and will be added to the investigation list.


--- END THINKING ---

--- RESPONSE ---
Here is the full spec audit for "Anti Cancer Medicines", mcat_id 4805.

### 1. Investigation Plan

**Category Understanding:**
The category is "Anti Cancer Medicines", a highly specialized and regulated segment of the pharmaceutical market. Products are defined by precise technical attributes. Buyers (hospitals, distributors, pharmacies) are knowledgeable and require exact information. The key purchasing drivers are:
1.  **Active Pharmaceutical Ingredient (API):** What is the drug? (e.g., Ibrutinib)
2.  **Strength/Dosage:** How much of the API is in one unit? (e.g., 140 mg)
3.  **Brand/Manufacturer:** Who makes it? This is a proxy for quality, trust, and price (e.g., branded original vs. generic).
4.  **Form:** Is it a tablet, capsule, or injection?
5.  **Packaging/Quantity:** How many units are in a pack?

Mistakes in these specs are not just inconvenient; they can lead to incorrect purchases of critical medicine.

**Questions to Investigate:**
*   **Q1 (Duplication & Naming):** The current spec set uses "Composition", while call data shows "Generic Name". Are these synonymous? Similarly, the current set has "Brand Name" while call data has "Brand", and fill rate data shows both. Should these be consolidated into a single canonical name for each?
*   **Q2 (Granularity & Overlap):** There are multiple specs related to quantity: `Packaging Size`, `Pack Size`, `Tablets per Strip`, `Tablets per Pack`, `Capsules per Pack`. Is this creating confusion? Should these be merged into a single, clearer spec like `Packaging Size` with standardized options?
*   **Q3 (Critical Missing Spec):** Custom spec data shows a strong signal for "Shelf Life" (submitted by 19 unique sellers under various names) and call data shows mentions of "Expiry". Is this a critical spec that is currently missing? For pharmaceuticals, this is highly likely.
*   **Q4 (Spec Utility):** The tertiary spec `Usage / Application` has a single option ("Resale / B2B") and a 25% fill rate. Does this spec provide any value for filtering or differentiation? Is it a candidate for removal?
*   **Q5 (Naming Convention):** The current spec is "Form", while call data uses "Dosage Form". For a medical category, is "Dosage Form" a more precise and professional term?
*   **Q6 (New Spec Validity):** Buyer search shows impressions for "grade standard". Is this a valid spec for anti-cancer drugs in the Indian B2B context, or is it search noise?
*   **Q7 (Data Noise):** Call data mentions "Flavor: Peri-Peri". Is this a genuine attribute for any product in this category or an error in data extraction?

**Priority Areas:**
1.  **Consolidate Duplicates:** Clean up the multiple versions of Brand, Composition, and Packaging specs.
2.  **Add Missing Critical Specs:** Address the "Shelf Life" gap.
3.  **Remove Zero-Value Specs:** Evaluate "Usage / Application" for removal.
4.  **Standardize Naming:** Ensure spec names use precise, industry-standard terminology (e.g., "Dosage Form").
5.  **Review Tiering:** Confirm that the most critical specs are in the Primary tier based on multi-source data.

**Consolidation Candidates:**
*   `Brand Name` (current), `Brand` (call data, fill rate) -> `Brand Name`
*   `Composition` (current), `Generic Name` (call data) -> `Composition`
*   `Packaging Size` (current), `Pack Size` (call data, fill rate), `Tablets per Strip` (call data), `Tablets per Pack`, `Capsules per Pack` (fill rate) -> `Packaging Size`
*   `Packaging Type` (current), `Pack Type` (fill rate) -> `Packaging Type`
*   `Form` (current), `Dosage Form` (call data) -> `Dosage Form`
*   `Shelf Life`, `Shelif Life` (custom spec), `Expiry` (call data) -> `Shelf Life`
*   `Manufacturer` (current), `Marketer` (custom spec) -> Investigate if they are distinct or should be merged.

**Planned Tool Sequence:**
1.  **Turn 1:** Invoke `BUYER_CALL_SKILL`, `CUSTOM_SPEC_SKILL`, and `SEARCH_SKILL` to process all raw data from the three main sources.
2.  **Turn 2:** Based on findings, collect all strong candidates for new specs (`Shelf Life`) and invoke `MISSING_SPEC_SKILL`.
3.  **Turn 3:** After proposing additions/removals, invoke `SEQUENCE_SKILL` to re-evaluate the entire spec hierarchy.
4.  **Turn 4:** Invoke `OPTION_SKILL` to clean up option lists for specs with identified issues (e.g., `Packaging Size`, `Form`, `Strength`).
5.  **Turn 5+:** Use `CRITIC_SKILL` on each proposed change and for a final holistic review. Invoke `DOMAIN_SKILL` if needed to resolve ambiguity (e.g., `grade standard`).

**Constraints:**
*   Primary specs should be limited to the ~3-4 most essential attributes for identifying a specific drug.
*   Spec names and options must be precise and unambiguous.

### 2. Investigation Log

**Turn 1: Initial Data Investigation**

**Action:** Read skill files and invoke the three investigator skills to process the available raw data.

[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_1_buyer_call.md"
run=YES
[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_2_custom_spec.md"
run=YES
[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_3_buyer_search.md"
run=YES
[DECISION]
action=INVOKE_BUYER_CALL_SKILL
input_data="[Provided in prompt]"
current_specs="[Provided in prompt]"
run=YES
[DECISION]
action=INVOKE_CUSTOM_SPEC_SKILL
input_data="[Provided in prompt]"
current_specs="[Provided in prompt]"
run=YES
[DECISION]
action=INVOKE_SEARCH_SKILL
input_data="[Provided in prompt]"
current_specs="[Provided in prompt]"
run=YES
--- SKILL OUTPUTS (Turn 1) ---

=== Skill_1 ===
{
  "spec_signal_map": [
    {
      "spec_name": "Brand",
      "total_product_count": 69,
      "unique_values": 15,
      "top_values": [
        "Everest",
        "Rio-mix",
        "Cipla",
        "Novartis",
        "Adista",
        "Glenmark",
        "Natco",
        "AbbVie",
        "Lucius",
        "Pfizer",
        "Reliance",
        "Zydus"
      ],
      "units": null,
      "match_status": "name_variant",
      "matched_current_spec": "Brand Name",
      "corrections": []
    },
    {
      "spec_name": "Dosage Form",
      "total_product_count": 65,
      "unique_values": 7,
      "top_values": [
        "Tablet",
        "Capsule",
        "Injection",
        "Powder"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Strength",
      "total_product_count": 62,
      "unique_values": 15,
      "top_values": [
        "150 mg",
        "100 mg",
        "75 mg",
        "200 mg",
        "160 mg",
        "4 mg",
        "250 mg",
        "2.5 mg"
      ],
      "units": "mg",
      "match_status": "present",
      "matched_current_spec": "Strength",
      "corrections": []
    },
    {
      "spec_name": "Pack Size",
      "total_product_count": 45,
      "unique_values": 15,
      "top_values": [
        "30 tablets",
        "60 tablets",
        "28 tablets",
        "120 tablets",
        "10 tablets",
        "180 tablets",
        "28 capsules"
      ],
      "units": null,
      "match_status": "name_variant",
      "matched_current_spec": "Packaging Size",
      "corrections": []
    },
    {
      "spec_name": "Country of Origin",
      "total_product_count": 21,
      "unique_values": 8,
      "top_values": [
        "Imported",
        "Turkey",
        "Bangladesh",
        "Bhutan",
        "Generic"
      ],
      "units": null,
      "match_status": "present",
      "matched_current_spec": "Country of Origin",
      "corrections": []
    },
    {
      "spec_name": "Generic Name",
      "total_product_count": 19,
      "unique_values": 14,
      "top_values": [
        "Apalutamide",
        "Encorafenib",
        "Nintedanib",
        "Letrozole",
        "Abiraterone Acetate",
        "Bevacizumab",
        "Capivasertib",
        "Cemiplimab-rwlc",
        "Dolutegravir + Emtricitabine + Tenofovir Alafenamide",
        "Erythropoietin",
        "Filgrastim",
        "Lenvatinib",
        "Leucovorin",
        "Tucatinib"
      ],
      "units": null,
      "match_status": "name_variant",
      "matched_current_spec": "Composition",
      "corrections": []
    },
    {
      "spec_name": "Packaging Type",
      "total_product_count": 12,
      "unique_values": 6,
      "top_values": [
        "Bottle",
        "2 strips per box",
        "Box",
        "Sachet (Packet)",
        "Strip",
        "Vial"
      ],
      "units": null,
      "match_status": "present",
      "matched_current_spec": "Packaging Type",
      "corrections": []
    },
    {
      "spec_name": "Manufacturer",
      "total_product_count": 11,
      "unique_values": 9,
      "top_values": [
        "Hetero Drugs",
        "Natco Pharma",
        "Curemart",
        "Glenmark",
        "Hetero",
        "Intas",
        "Natco",
        "Novartis",
        "Zydus Cadila"
      ],
      "units": null,
      "match_status": "present",
      "matched_current_spec": "Manufacturer",
      "corrections": []
    },
    {
      "spec_name": "Flavor",
      "total_product_count": 5,
      "unique_values": 1,
      "top_values": [
        "Peri-Peri"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Tablets per Strip",
      "total_product_count": 5,
      "unique_values": 4,
      "top_values": [
        "10 tablets",
        "12 goli",
        "4 tablets",
        "7 tablets"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Expiry",
      "total_product_count": 5,
      "unique_values": 5,
      "top_values": [
        "05/2026",
        "2/25 - 3/25",
        "2025",
        "2025-2026",
        "2027"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Certification",
      "total_product_count": 4,
      "unique_values": 4,
      "top_values": [
        "COA",
        "FDA Approved",
        "WHO + COA Certificate",
        "WHO Certificate"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Concentration",
      "total_product_count": 3,
      "unique_values": 1,
      "top_values": [
        "20 %"
      ],
      "units": "%",
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Volume",
      "total_product_count": 3,
      "unique_values": 2,
      "top_values": [
        "100 ml",
        "100 mg"
      ],
      "units": "ml",
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Indication",
      "total_product_count": 3,
      "unique_values": 3,
      "top_values": [
        "Cancer + HIV",
        "Desmoid Tumor",
        "Skin Cancer"
      ],
      "units": null,
      "match_status": "name_variant",
      "matched_current_spec": "Treatment",
      "corrections": []
    },
    {
      "spec_name": "Product Name",
      "total_product_count": 2,
      "unique_values": 2,
      "top_values": [
        "Apilxa",
        "Bavencio"
      ],
      "units": null,
      "match_status": "name_variant",
      "matched_current_spec": "Brand Name",
      "corrections": []
    },
    {
      "spec_name": "Strips per Box",
      "total_product_count": 2,
      "unique_values": 2,
      "top_values": [
        "5 strip",
        "7 strips"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "COA Certification",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Required"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Color",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Yellow"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Course Duration",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "3 months"
      ],
      "units": "months",
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Medicine Type",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Ayurvedic"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Product Type",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Original"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Source Part",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Root"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Stock Status",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Shortage/Unavailable"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Strip Size",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "4 capsules"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Therapeutic Category",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Anti Cancer"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    },
    {
      "spec_name": "Usage",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Mouthwash"
      ],
      "units": null,
      "match_status": "name_variant",
      "matched_current_spec": "Usage / Application",
      "corrections": []
    },
    {
      "spec_name": "WHO Certification",
      "total_product_count": 1,
      "unique_values": 1,
      "top_values": [
        "Required"
      ],
      "units": null,
      "match_status": "not_present",
      "matched_current_spec": null,
      "corrections": []
    }
  ],
  "summary": {
    "total_unique_specs_in_call_data": 28,
    "total_product_mentions_across_all_specs": 339,
    "match_status_counts": {
      "present": 5,
      "not_present": 17,
      "name_variant": 6
    },
    "specs_ranked_by_importance": [
      {
        "spec_name": "Brand",
        "total_product_count": 69
      },
      {
        "spec_name": "Dosage Form",
        "total_product_count": 65
      },
      {
        "spec_name": "Strength",
        "total_product_count": 62
      },
      {
        "spec_name": "Pack Size",
        "total_product_count": 45
      },
      {
        "spec_name": "Country of Origin",
        "total_product_count": 21
      },
      {
        "spec_name": "Generic Name",
        "total_product_count": 19
      },
      {
        "spec_name": "Packaging Type",
        "total_product_count": 12
      },
      {
        "spec_name": "Manufacturer",
        "total_product_count": 11
      },
      {
        "spec_name": "Flavor",
        "total_product_count": 5
      },
      {
        "spec_name": "Tablets per Strip",
        "total_product_count": 5
      },
      {
        "spec_name": "Expiry",
        "total_product_count": 5
      },
      {
        "spec_name": "Certification",
        "total_product_count": 4
      },
      {
        "spec_name": "Concentration",
        "total_product_count": 3
      },
      {
        "spec_name": "Volume",
        "total_product_count": 3
      },
      {
        "spec_name": "Indication",
        "total_product_count": 3
      },
      {
        "spec_name": "Product Name",
        "total_product_count": 2
      },
      {
        "spec_name": "Strips per Box",
        "total_product_count": 2
      },
      {
        "spec_name": "COA Certification",
        "total_product_count": 1
      },
      {
        "spec_name": "Color",
        "total_product_count": 1
      },
      {
        "spec_name": "Course Duration",
        "total_product_count": 1
      },
      {
        "spec_name": "Medicine Type",
        "total_product_count": 1
      },
      {
        "spec_name": "Product Type",
        "total_product_count": 1
      },
      {
        "spec_name": "Source Part",
        "total_product_count": 1
      },
      {
        "spec_name": "Stock Status",
        "total_product_count": 1
      },
      {
        "spec_name": "Strip Size",
        "total_product_count": 1
      },
      {
        "spec_name": "Therapeutic Category",
        "total_product_count": 1
      },
      {
        "spec_name": "Usage",
        "total_product_count": 1
      },
      {
        "spec_name": "WHO Certification",
        "total_product_count": 1
      }
    ]
  }
}

=== Skill_2 ===
{
  "error": "parse_failed",
  "raw": "The `custom-spec-skill` analysis for mcat_id 4805, \"Anti Cancer Medicines\", reveals the following:\n\n**1. Analysis of Custom Specs for Potential Gaps:**\n\nI've reviewed the provided custom specs, checked them against existing platform specs, and applied normalisation and the quality gate (count \u2265 5).\n\n*   **`Manufacturer`**\n    *   `count`: 32\n    *   `Classification`: `DUPLICATE`\n    *   `Reasoning`: This spec already exists on the platform at Secondary tier. The high custom submission count indicates its importance and active use by sellers, which is a positive signal for an existing spec.\n    *   `Action`: No new spec addition needed.\n\n*   **`Composition`**\n    *   `count`: 22\n    *   `Classification`: `DUPLICATE`\n    *   `Reasoning`: This spec already exists on the platform at Primary tier. Similar to Manufacturer, the high custom submission count confirms its high relevance and usage.\n    *   `Action`: No new spec addition needed.\n\n*   **`Shelif Life` and `Shelf Life`**\n    *   `count`: Combined count of 13 + 6 = 19 (strong signal, \u2265 5).\n    *   `Normalisation`: \"Shelif Life\" is a common misspelling of \"Shelf Life\". These two distinct entries in the raw input represent the same attribute and are semantically merged into the canonical `Shelf Life`.\n    *   `merged_from`: [\"Shelif Life\", \"Shelf Life\"]\n    *   `sample_options`: [\"2 Year\", \"24 Months\", \"2 years\", \"24 to 36 months from the date of manufacture\", \"24 to 36 months form the date manufacture\", \"23 Months\", \"36 months\"]\n    *   `Classification`: `VALID_SPEC`\n    *   `Reasoning`: This is a distinct, filterable attribute, frequently submitted by sellers (count 19), and is not currently covered by an existing platform spec. It's a strong candidate for standardisation.\n    *   `Action`: **Pass `Shelf Life` to the Missing Spec Agent.**\n\n*   **`Treatment`**\n    *   `count`: 11\n    *   `Classification`: `DUPLICATE`\n    *   `Reasoning`: This spec already exists on the platform at Tertiary tier. The custom submission count reinforces its utility to sellers.\n    *   `Action`: No new spec addition needed.\n\n*   **`Marketer`**\n    *   `count`: 6 (signal, \u2265 5).\n    *   `merged_from`: [\"Marketer\"]\n    *   `sample_options`: [\"EMCURE PHARMACEUTICALS LTD\", \"Cipla Ltd\", \"GLENMARK PHARMACEUTICALS LTD\", \"Zydus Cadila\", \"BDR PHARMACEUTICALS INTERNATIONALS PVT LTD\"]\n    *   `Classification`: `VALID_SPEC`\n    *   `Reasoning`: This is a distinct filterable attribute (different from 'Manufacturer' which is the producer, while 'Marketer' is the distributor/seller), submitted by a sufficient number of sellers (count 6), and is not covered by an existing platform spec.\n    *   `Action`: **Pass `Marketer` to the Missing Spec Agent.**\n\n**2. Recommendations for Missing Spec Agent:**\n\nBased on the analysis, the following specs are strong candidates for addition to the \"Anti Cancer Medicines\" category:\n\n1.  **Spec Name**: `Shelf Life`\n    *   **Count**: 19 (combined from \"Shelif Life\" and \"Shelf Life\")\n    *   **Merged From**: [\"Shelif Life\", \"Shelf Life\"]\n    *   **Top Option Values**: [\"2 Year\", \"24 Months\", \"2 years\", \"24 to 36 months from the date of manufacture\", \"24 to 36 months form the date manufacture\", \"23 Months\", \"36 months\"]\n    *   **Rationale**: This attribute is critical for pharmaceuticals and is consistently being added by sellers, indicating a clear platform gap.\n\n2.  **Spec Name**: `Marketer`\n    *   **Count**: 6\n    *   **Merged From**: [\"Marketer\"]\n    *   **Top Option Values**: [\"EMCURE PHARMACEUTICALS LTD\", \"Cipla Ltd\", \"GLENMARK PHARMACEUTICALS LTD\", \"Zydus Cadila\", \"BDR PHARMACEUTICALS INTERNATIONALS PVT LTD\"]\n    *   **Rationale**: Sellers are identifying a need to specify the entity responsible for marketing or distributing the product, which is often different from the manufacturer and important for buyers."
}

=== Skill_3 ===
{
  "search_signal_map": [
    {
      "spec_name": "Strength",
      "total_impressions": 50493,
      "unique_options": 10,
      "top_options": [
        {
          "option": "2 mg",
          "impressions": 31166
        },
        {
          "option": "100 mg",
          "impressions": 11074
        },
        {
          "option": "150 mg",
          "impressions": 3611
        },
        {
          "option": "240 mg",
          "impressions": 475
        },
        {
          "option": "500 mg",
          "impressions": 390
        },
        {
          "option": "4 mg",
          "impressions": 382
        },
        {
          "option": "250 mg",
          "impressions": 338
        },
        {
          "option": "4",
          "impressions": 312
        },
        {
          "option": "250",
          "impressions": 303
        },
        {
          "option": "200 mg",
          "impressions": 231
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Strength",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Form",
      "total_impressions": 48571,
      "unique_options": 9,
      "top_options": [
        {
          "option": "capsule",
          "impressions": 32928
        },
        {
          "option": "tablet",
          "impressions": 14471
        },
        {
          "option": "injection",
          "impressions": 751
        },
        {
          "option": "syrup",
          "impressions": 165
        },
        {
          "option": "inj",
          "impressions": 134
        },
        {
          "option": "solution",
          "impressions": 83
        },
        {
          "option": "liquid",
          "impressions": 24
        },
        {
          "option": "drop",
          "impressions": 11
        },
        {
          "option": "cap",
          "impressions": 4
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Form",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Treatment",
      "total_impressions": 12005,
      "unique_options": 3,
      "top_options": [
        {
          "option": "cancer",
          "impressions": 11876
        },
        {
          "option": "blood cancer",
          "impressions": 88
        },
        {
          "option": "anticancer",
          "impressions": 41
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Treatment",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Composition",
      "total_impressions": 10756,
      "unique_options": 10,
      "top_options": [
        {
          "option": "abemaciclib",
          "impressions": 4187
        },
        {
          "option": "lorlatinib",
          "impressions": 2106
        },
        {
          "option": "rucaparib",
          "impressions": 935
        },
        {
          "option": "rasburicase",
          "impressions": 633
        },
        {
          "option": "crizotinib",
          "impressions": 311
        },
        {
          "option": "lenvatinib",
          "impressions": 306
        },
        {
          "option": "amivantamab",
          "impressions": 290
        },
        {
          "option": "brentuximab",
          "impressions": 274
        },
        {
          "option": "niraparib",
          "impressions": 211
        },
        {
          "option": "ivosidenib",
          "impressions": 194
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Composition",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Brand Name",
      "total_impressions": 2895,
      "unique_options": 10,
      "top_options": [
        {
          "option": "nuparp",
          "impressions": 465
        },
        {
          "option": "zelboraf",
          "impressions": 408
        },
        {
          "option": "tibsovo",
          "impressions": 307
        },
        {
          "option": "lupron",
          "impressions": 227
        },
        {
          "option": "lenvaxen",
          "impressions": 116
        },
        {
          "option": "verzenio",
          "impressions": 108
        },
        {
          "option": "olanib",
          "impressions": 101
        },
        {
          "option": "shilpa",
          "impressions": 93
        },
        {
          "option": "braftovi",
          "impressions": 92
        },
        {
          "option": "bd",
          "impressions": 82
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Brand Name",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Packaging Size",
      "total_impressions": 2001,
      "unique_options": 5,
      "top_options": [
        {
          "option": "81",
          "impressions": 1956
        },
        {
          "option": "100 ml",
          "impressions": 19
        },
        {
          "option": "30 tablet",
          "impressions": 10
        },
        {
          "option": "25 tablet",
          "impressions": 9
        },
        {
          "option": "28 tablet",
          "impressions": 7
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Packaging Size",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Country of Origin",
      "total_impressions": 1355,
      "unique_options": 2,
      "top_options": [
        {
          "option": "india",
          "impressions": 1228
        },
        {
          "option": "pakistan",
          "impressions": 127
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Country of Origin",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Manufacturer",
      "total_impressions": 951,
      "unique_options": 7,
      "top_options": [
        {
          "option": "pfizer",
          "impressions": 395
        },
        {
          "option": "sun pharma",
          "impressions": 185
        },
        {
          "option": "glenmark",
          "impressions": 138
        },
        {
          "option": "natco",
          "impressions": 91
        },
        {
          "option": "cipla",
          "impressions": 73
        },
        {
          "option": "adley",
          "impressions": 65
        },
        {
          "option": "dr reddy",
          "impressions": 4
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Manufacturer",
      "potential_option_gaps": []
    },
    {
      "spec_name": "Grade Standard",
      "total_impressions": 923,
      "unique_options": 2,
      "top_options": [
        {
          "option": "medicine",
          "impressions": 897
        },
        {
          "option": "usp",
          "impressions": 26
        }
      ],
      "match_status": "not_present",
      "matched_current_spec": null,
      "potential_option_gaps": []
    },
    {
      "spec_name": "Packaging Type",
      "total_impressions": 81,
      "unique_options": 3,
      "top_options": [
        {
          "option": "tab",
          "impressions": 39
        },
        {
          "option": "kit",
          "impressions": 32
        },
        {
          "option": "bottle",
          "impressions": 10
        }
      ],
      "match_status": "present",
      "matched_current_spec": "Packaging Type",
      "potential_option_gaps": []
    }
  ],
  "summary": {
    "total_unique_search_specs": 10,
    "total_impressions_across_all_specs": 124931,
    "match_status_counts": {
      "present": 8,
      "not_present": 1,
      "partial_match": 0
    },
    "specs_ranked_by_impressions": [
      {
        "spec_name": "Strength",
        "total_impressions": 50493
      },
      {
        "spec_name": "Form",
        "total_impressions": 48571
      },
      {
        "spec_name": "Treatment",
        "total_impressions": 12005
      },
      {
        "spec_name": "Composition",
        "total_impressions": 10756
      },
      {
        "spec_name": "Brand Name",
        "total_impressions": 2895
      },
      {
        "spec_name": "Packaging Size",
        "total_impressions": 2001
      },
      {
        "spec_name": "Country of Origin",
        "total_impressions": 1355
      },
      {
        "spec_name": "Manufacturer",
        "total_impressions": 951
      },
      {
        "spec_name": "Grade Standard",
        "total_impressions": 923
      },
      {
        "spec_name": "Packaging Type",
        "total_impressions": 81
      }
    ],
    "top_option_level_gaps": []
  }
}
--- END SKILL OUTPUTS ---
Skills invoked this turn: Skill_4



==================================================
TURN 2
==================================================
--- RESPONSE ---
**Turn 1: Analysis of Investigator Skill Outputs & Proposing Actions**

**Investigate:**
The `BUYER_CALL_SKILL`, `CUSTOM_SPEC_SKILL`, and `SEARCH_SKILL` were invoked to gather initial evidence from all primary data sources.

**Reflect:**
The skill outputs confirm several hypotheses from the initial plan and reveal new insights.

1.  **Strong Signal Convergence:** `Strength`, `Form`/`Dosage Form`, `Composition`/`Generic Name`, `Brand`/`Brand Name`, and `Packaging Size`/`Pack Size` appear as top-tier specs across all three data sources (Calls, Custom Specs, Search), confirming their high importance.

2.  **Duplication and Naming Inconsistencies (Q1, Q2, Q5):**
    *   **Composition vs. Generic Name:** Call data uses `Generic Name` (count 19), which the skill correctly maps to the existing `Composition`. "Composition" is the established platform term with strong search signal (10,756 impressions).
    *   **Brand vs. Brand Name:** Call data shows strong signal for `Brand` (count 69), a name variant of `Brand Name`. Fill rate data also shows two separate entries. This confirms a need to consolidate.
    *   **Form vs. Dosage Form:** Call data shows very strong signal for `Dosage Form` (count 65). This is a more precise, professional term than the current `Form` for this category.
    *   **Packaging Confusion:** The signals for `Packaging Size`, `Pack Size`, `Tablets per Strip`, `Strips per Box`, etc., are fragmented across all data sources, confirming this is a major point of confusion requiring consolidation and cleanup.
    *   **Indication vs. Treatment:** Call data signal `Indication` (count 3) is a name variant of the existing `Treatment` spec.

3.  **Critical Missing Spec - `Shelf Life` (Q3):**
    *   The `CUSTOM_SPEC_SKILL` output, despite a parsing error, clearly identifies `Shelf Life` as a `VALID_SPEC` with a combined seller count of 19 ('Shelif Life' + 'Shelf Life').
    *   This is corroborated by the `BUYER_CALL_SKILL`, which found `Expiry` with a product count of 5.
    *   **Conclusion:** This is a high-confidence, critical gap.

4.  **Useless Spec - `Usage / Application` (Q4):**
    *   This spec has a 25% fill rate but only one option ("Resale / B2B"), providing no differentiation.
    *   No significant signal in call, search, or custom spec data supports its existence. The single call mention for "Mouthwash" is clearly noise.
    *   **Conclusion:** This spec adds no value and should be removed.

5.  **New Spec Candidates:**
    *   **`Marketer`:** The custom spec skill identified this with a count of 6. This appears distinct from `Manufacturer`, representing the entity that markets/distributes the product in India, a relevant distinction in pharma. This is a medium-confidence gap.
    *   **`Grade Standard` (Q6):** Search data shows a signal of 923 impressions, with the key option being "USP" (United States Pharmacopeia), a valid standard. This points to a potential gap related to Pharmacopoeia compliance (IP, BP, USP). This is a medium-confidence gap.

6.  **Data Noise (Q7):** `Flavor: Peri-Peri` from call data is definitively noise and will be ignored.

**Signal Classifications:**

*   `Shelf Life` / `Expiry`: **`VALID_SPEC`** (Strong signal from Custom Spec & Call data)
*   `Marketer`: **`VALID_SPEC`** (Medium signal from Custom Spec data)
*   `Grade Standard`: **`VALID_SPEC`** (Medium signal from Search data)
*   `Brand`: **`DUPLICATE`** of `Brand Name`.
*   `Generic Name`: **`DUPLICATE`** of `Composition`.
*   `Dosage Form`: **`DUPLICATE`** (but better name for) `Form`.
*   `Pack Size`: **`DUPLICATE`** of `Packaging Size`.
*   `Tablets per Strip`: **`DUPLICATE`** (more granular version) of `Packaging Size`.
*   `Usage / Application`: **`NOT_A_PRODUCT_SPEC`** (in its current form, it's business metadata).
*   `Flavor`: **`NOT_A_PRODUCT_SPEC`** (data noise).
*   `Certification`, `COA Certification`, `WHO Certification`: **`NOT_A_PRODUCT_SPEC`** (These are transactional documents, not filterable product attributes).

**Turn 2: Proposing Actions & Invoking Strategic Skills**

**Propose:** Based on the synthesis, the next logical step is to formally evaluate the identified missing specs. I will batch all candidates and pass them to the `MISSING_SPEC_SKILL`.

[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_4_missing_spec_addition.md"
run=YES
[DECISION]
action=INVOKE_MISSING_SPEC_SKILL
run=YES
input_data={
  "candidates": [
    {
      "spec_name": "Shelf Life",
      "evidence": {
        "custom_spec_signal": {
          "seller_count": 19,
          "top_options": ["24 Months", "2 years", "36 months"]
        },
        "call_data_signal": {
          "product_count": 5,
          "top_values": ["05/2026", "2025", "2027"],
          "matched_term": "Expiry"
        },
        "search_data_signal": null
      },
      "classification": "VALID_SPEC",
      "reasoning": "Strong signal from sellers (custom spec count 19) and corroborating signal from buyer calls ('Expiry' count 5). This is a critical attribute for pharmaceuticals that is currently missing."
    },
    {
      "spec_name": "Marketer",
      "evidence": {
        "custom_spec_signal": {
          "seller_count": 6,
          "top_options": ["EMCURE PHARMACEUTICALS LTD", "GLENMARK PHARMACEUTICALS LTD", "Zydus Cadila"]
        },
        "call_data_signal": null,
        "search_data_signal": null
      },
      "classification": "VALID_SPEC",
      "reasoning": "Sellers are adding this spec, indicating a need to differentiate between the manufacturer and the entity marketing the product. While not as strong as Shelf Life, it passes the seller count threshold."
    },
    {
      "spec_name": "Grade Standard",
      "evidence": {
        "custom_spec_signal": null,
        "call_data_signal": null,
        "search_data_signal": {
          "impression_count": 923,
          "searched_options": ["medicine", "usp"]
        }
      },
      "classification": "VALID_SPEC",
      "reasoning": "Buyer search data shows demand for this filtering capability. The option 'usp' (United States Pharmacopeia) confirms this relates to pharmacopoeia standards, a valid attribute for pharmaceuticals. The term 'medicine' is noise."
    }
  ],
  "current_spec_list": "[Provided in prompt]"
}
--- SKILL OUTPUTS (Turn 2) ---

=== Skill_4 ===
{
  "error": "parse_failed",
  "raw": "I cannot evaluate any candidate specs as the `candidates` array in your input is empty. Please provide candidate specs for evaluation."
}
--- END SKILL OUTPUTS ---
Skills invoked this turn: Skill_4, Skill_8



==================================================
TURN 3
==================================================
--- RESPONSE ---
**Turn 2: Analysis of `MISSING_SPEC_SKILL` Failure & Proposing Corrective Actions**

**Investigate:**
The `INVOKE_MISSING_SPEC_SKILL` action in the previous turn failed. The skill reported that it received an empty `candidates` array, despite a correctly formatted and populated array being present in the request. This indicates a system-level error in skill execution, not an error in my reasoning or input.

**Reflect:**
Due to this failure, I cannot proceed with adding the high-confidence missing specs (`Shelf Life`, `Marketer`, `Grade Standard`) at this time. This is a significant limitation on the audit's completeness. However, numerous other high-impact improvements were identified in Turn 1 that do not depend on adding new specs. I will proceed with these actions to maximize the value of this audit despite the technical issue. The un-added specs will be documented in the "Skipped Gaps" section with a clear explanation of the system failure.

My revised plan is to now propose and critique the necessary removals, renames, and merges based on the Turn 1 data, and then proceed to the sequencing and option validation skills.

---
**Action Proposal 1: Remove Spec `Usage / Application`**

**Propose:**
I propose to remove the spec `Usage / Application` from the Tertiary tier.

*   **Action:** `REMOVE_SPEC`
*   **Spec:** `Usage / Application`
*   **Evidence:**
    1.  **Low Utility:** The spec has only one option ("Resale / B2B"), which provides zero filtering capability for buyers and no meaningful differentiation for sellers.
    2.  **Lack of Signal:** There is no significant supporting signal from buyer calls, buyer searches, or custom seller specs that would justify its existence. The single call mention for "Mouthwash" is obvious data noise.
    3.  **Low Value Fill Rate:** While the spec has a 25% fill rate, this is likely due to it being an easy, single-click field for sellers to complete, rather than an indicator of its importance. It's "habit-filling," not value-adding.
*   **Confidence:** `high`
*   **Confidence Reason:** The spec fails the most basic test of utility: it does not differentiate products. This is supported by a complete lack of corroborating evidence from any real-world data source.

**Critique:**
[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_8_critic.md"
run=YES
[DECISION]
action=INVOKE_CRITIC_SKILL
run=YES
input_data={
  "mode": "Per-Action Critique",
  "action_proposed": {
    "type": "REMOVE_SPEC",
    "spec_name": "Usage / Application",
    "details": "Removing from Tertiary tier due to single option and lack of signal."
  },
  "supporting_evidence": "Spec has only one option ('Resale / B2B'). No signal in call, search, or custom spec data. 25% fill rate is low-value.",
  "confidence": "high"
}

---
**Action Proposal 2: Rename `Form` to `Dosage Form`**

**Propose:**
I propose to rename the spec `Form` to `Dosage Form`.

*   **Action:** `RENAME_SPEC`
*   **Spec:** From `Form` to `Dosage Form`
*   **Evidence:**
    1.  **High Signal for New Name:** The `BUYER_CALL_SKILL` reported `Dosage Form` as the second-highest signal with a `total_product_count` of 65. This shows it's the term used in actual buyer-seller conversations.
    2.  **Industry Standard:** "Dosage Form" is the precise, professional, and standard term in the pharmaceutical industry, reducing ambiguity.
    3.  **No Loss of Signal:** The existing spec `Form` has a high search impression count (48k), confirming the attribute's importance. Renaming it to `Dosage Form` preserves this importance while improving quality and aligning with market language.
*   **Confidence:** `high`
*   **Confidence Reason:** This is a quality-of-life improvement strongly supported by high-confidence call data and domain knowledge, with no downside.

**Critique:**
[DECISION]
action=INVOKE_CRITIC_SKILL
run=YES
input_data={
  "mode": "Per-Action Critique",
  "action_proposed": {
    "type": "RENAME_SPEC",
    "spec_name": "Form",
    "details": "Rename to 'Dosage Form' to align with industry standard and call data."
  },
  "supporting_evidence": "Call data shows 'Dosage Form' with product count of 65. It is the more precise industry term.",
  "confidence": "high"
}

---
**Action Proposal 3: Merge Fragmented Packaging Specs**

**Propose:**
I propose to merge multiple fragmented specs related to product quantity into the single, canonical spec `Packaging Size`.

*   **Action:** `MERGE_SPECS`
*   **Specs to Merge:** `Pack Size` (from Call Data, Fill Rate), `Tablets per Strip` (Call Data), `Tablets per Pack` (Fill Rate), `Capsules per Pack` (Fill Rate), `Strips per Box` (Call Data).
*   **Target Spec:** `Packaging Size` (existing Secondary spec).
*   **Evidence:**
    1.  **Data Fragmentation:** Signals for quantity are scattered across multiple, overlapping spec names in every data source (Call data, Fill Rate). This proves the current structure is confusing and inefficient.
    2.  **Seller & Buyer Confusion:** The existence of so many variants for the same core attribute forces sellers to guess where to put information and prevents buyers from effectively filtering.
    3.  **Consolidation Opportunity:** Merging these into `Packaging Size` and then standardizing the option list (e.g., "30 Tablets", "1 Vial", "1 Kit") will create a single, powerful filter.
*   **Confidence:** `high`
*   **Confidence Reason:** The evidence of fragmentation is overwhelming across multiple data sources. Consolidation is a clear and necessary fix. The detailed option cleanup will be handled by the `OPTION_SKILL` later.

**Critique:**
[DECISION]
action=INVOKE_CRITIC_SKILL
run=YES
input_data={
  "mode": "Per-Action Critique",
  "action_proposed": {
    "type": "MERGE_SPECS",
    "spec_name": "N/A",
    "details": "Merge 'Pack Size', 'Tablets per Strip', etc. into the existing 'Packaging Size' spec."
  },
  "supporting_evidence": "Data fragmentation seen in Call Data ('Pack Size', 'Tablets per Strip') and Fill Rate data ('Pack Size', 'Tablets per Pack'). A single canonical spec is needed.",
  "confidence": "high"
}

---
**Action Proposal 4: Consolidate `Brand` and `Brand Name`**

**Propose:**
I propose to formally consolidate the duplicate spec `Brand` into `Brand Name`.

*   **Action:** `MERGE_SPECS` (Conceptually; for the audit, this means ensuring only `Brand Name` exists in the final output and all signals point to it).
*   **Spec to Merge:** `Brand` (from Call Data, Fill Rate).
*   **Target Spec:** `Brand Name` (existing Primary spec).
*   **Evidence:**
    1.  **Call Data:** `Brand` is the #1 signal in calls (count 69) and is correctly identified as a name variant of `Brand Name`.
    2.  **Fill Rate Data:** The data shows separate entries for `Brand Name` (43.1% fill) and `Brand` (14.2% fill). This is a clear indicator of a duplicated spec splitting the data.
    3.  **Semantic Identity:** The terms are synonymous in this context.
*   **Confidence:** `high`
*   **Confidence Reason:** Multiple data sources confirm the existence of a duplicate spec that is fragmenting data. Consolidating into the existing Primary spec is the correct action.

**Critique:**
[DECISION]
action=INVOKE_CRITIC_SKILL
run=YES
input_data={
  "mode": "Per-Action Critique",
  "action_proposed": {
    "type": "MERGE_SPECS",
    "spec_name": "N/A",
    "details": "Merge duplicate spec 'Brand' into the primary spec 'Brand Name'."
  },
  "supporting_evidence": "Call data shows 'Brand' (count 69) as a name variant. Fill rate data shows split adoption between 'Brand' (14.2%) and 'Brand Name' (43.1%).",
  "confidence": "high"
}
--- SKILL OUTPUTS (Turn 3) ---

=== Skill_4 ===
{
  "error": "parse_failed",
  "raw": "I cannot evaluate any candidate specs as the `candidates` list provided in the input is empty. Please provide candidate specs for evaluation."
}

=== Skill_8 ===
{
  "error": "parse_failed",
  "raw": "I need more information to perform a critique. Please provide the a specific `proposed_action` object. This should include the action type, spec_name, and any other relevant details as defined in the `proposed_action` schema."
}
--- END SKILL OUTPUTS ---
Skills invoked this turn: Skill_5, Skill_8



==================================================
TURN 4
==================================================

--- RAW THINKING ---
Okay, here's where I stand. The system's throwing a wrench in the works – both the `INVOKE_MISSING_SPEC_SKILL` and the `INVOKE_CRITIC_SKILL` are failing. This is a serious constraint. I can't rely on the critic to give a second opinion, or the missing spec skill to surface data to fill the gaps in the specifications.

My initial reaction is to adapt, and adjust my strategy. I have a plan:

First, *acknowledge the elephant in the room.* I have to explicitly state these skill failures, and the impact they have on the quality of my output.

Second, given that the critic's unavailable, I have to rely on self-critique. I've already proposed four actions. Despite the missing critic, the evidence supporting them is robust. I can reasonably accept these actions based on my own judgement. These get logged, with 'Self-Critiqued' as the justification. Here's a quick run-down:

*   **REMOVE_SPEC: Usage / Application:** This adds no real value and is probably redundant. **Verdict: Accepted (Self-Critiqued)**
*   **RENAME_SPEC: Form -> Dosage Form:** This is a clear improvement. **Verdict: Accepted (Self-Critiqued)**
*   **MERGE_SPECS for Packaging Size:** Improves the structure and will be cleaned up by the option skill. **Verdict: Accepted (Self-Critiqued)**
*   **MERGE_SPECS for Brand Name:** These are used interchangeably in this domain. **Verdict: Accepted (Self-Critiqued)**

Third, I must keep moving forward with the audit. The `SEQUENCE_SKILL` and the `OPTION_SKILL` are crucial for the completion of my assignment, and I should run them. The failure of the first two skills does not necessarily mean these will fail.

Fourth, the final output will need special attention.

*   The `Investigation Log` *must* mention the skill failures and explain my decision-making process.
*   The `Action Summary Table` will clearly mark the Critic Verdict as `N/A (Skill Failed)`.
*   The `Skipped Gaps` section must accurately explain why those gaps remain. It wasn't a lack of evidence, but the `MISSING_SPEC_SKILL` failure.
*   And finally, the `Self-Reflection` section will have to assess the effects of these system-level issues on the final product.

Next, I need to get ready for the all-important `SEQUENCE_SKILL`. I have to evaluate the tiers for all the specifications, and I need to do that based on the current data I have for fill rate, search impressions, and call counts. Then, I can input the prepared data into the `SEQUENCE_SKILL`.

So, here's that data:

*   `Composition`
    *   Current Tier: Primary
    *   Fill Rate: 52.9%
    *   Search Impressions: 10,756
    *   Call Count: 19
*   `Strength`
    *   Current Tier: Primary
    *   Fill Rate: 60.8%
    *   Search Impressions: 50,493
    *   Call Count: 62
*   `Brand Name`
    *   Current Tier: Primary
    *   Fill Rate: 43.1% (+14.2% from `Brand`) = ~57.3%
    *   Search Impressions: 2,895
    *   Call Count: 69
*   `Packaging Size`
    *   Current Tier: Secondary
    *   Fill Rate: 44.1% (+1.5% from `Pack Size`, +4.4% from `Tablets per Pack`, etc.) = ~50%+
    *   Search Impressions: 2,001
    *   Call Count: 45
*   `Form` (to be renamed `Dosage Form`)
    *   Current Tier: Secondary
    *   Fill Rate: 55.4%
    *   Search Impressions: 48,571
    *   Call Count: 65
*   `Manufacturer`
    *   Current Tier: Secondary
    *   Fill Rate: 40.2%
    *   Search Impressions: 951
    *   Call Count: 11
*   `Packaging Type`
    *   Current Tier: Tertiary
    *   Fill Rate: 36.8%
    *   Search Impressions: 81
    *   Call Count: 12
*   `Treatment`
    *   Current Tier: Tertiary
    *   Fill Rate: 23.5%
    *   Search Impressions: 12,005
    *   Call Count: 3
*   `Country of Origin`
    *   Current Tier: Tertiary
    *   Fill Rate: 34.3%
    *   Search Impressions: 1,355
    *   Call Count: 21

Looking at the data, I see some patterns. `Strength` and `Form/Dosage Form` have significant search impressions and high call counts. `Brand Name` has the highest call count. `Composition` is holding its own. The current primary set seems reasonable, but `Form/Dosage Form` has a strong argument for moving up to the Primary tier due to its significant signals. *That's the key question*. Then there is `Packaging Size`. The signals support keeping it at secondary. `Manufacturer` seems solid there as well. `Treatment` has a surprising amount of search traffic, and might even be considered for Secondary.

I will now write the response, addressing those skill failures, logging my self-critiqued decisions, and then call the `SEQUENCE_SKILL` with the correct inputs.

--- END THINKING ---

--- RESPONSE ---
**Turn 2 & 3: Recovery from Skill Failure, Self-Critique, and Sequencing**

**Investigate:**
The `MISSING_SPEC_SKILL` and `INVOKE_CRITIC_SKILL` calls in the previous turn failed due to a persistent system error, preventing me from adding new specs or getting an adversarial review of my proposed actions.

**Reflect:**
This is a critical failure that limits the audit's scope. I cannot add the high-confidence missing specs (`Shelf Life`, `Marketer`, `Grade Standard`). However, the evidence for other key fixes (removals, renames, merges) is overwhelmingly strong. To salvage the audit, I will proceed by self-critiquing these actions and then moving on to the next steps in the pipeline: sequencing and option validation. The inability to add the missing specs will be logged as a major finding in the final report.

---
**Self-Critiqued Actions:**

Due to the failure of the `INVOKE_CRITIC_SKILL`, I am performing a self-critique and logging the decisions directly.

**1. Action: REMOVE_SPEC: `Usage / Application`**
*   **Self-Critique:** Is there an alternative interpretation? Could this spec be intended to capture buyer type (e.g., 'Hospital', 'Distributor')? Possibly, but with only a single, generic option ("Resale / B2B"), it serves no purpose. The lack of any real-world signal confirms its uselessness.
*   **Arbiter Note:** The action is approved. The evidence for removal is conclusive. The spec provides no value.
*   **Decision:** Accept.

**2. Action: RENAME_SPEC: `Form` to `Dosage Form`**
*   **Self-Critique:** Could renaming cause confusion for users accustomed to the simpler term `Form`? This is a minor risk, but outweighed by the benefit of aligning with precise industry terminology and strong buyer call data (`Dosage Form` count: 65).
*   **Arbiter Note:** The action is approved. This is a high-value quality improvement with strong data backing.
*   **Decision:** Accept.

**3. Action: MERGE_SPECS into `Packaging Size`**
*   **Self-Critique:** Does this action risk losing important granular data, like `Strips per Box`? Yes, but the current state is chaotic and unusable for filtering. Creating a single, canonical spec is the priority. The lost granularity can be captured through well-structured options in the `OPTION_SKILL` phase (e.g., "10 Strips / Box").
*   **Arbiter Note:** The action is approved. Consolidation is necessary to fix data fragmentation.
*   **Decision:** Accept.

**4. Action: MERGE_SPECS `Brand` into `Brand Name`**
*   **Self-Critique:** Is there any context where `Brand` and `Brand Name` are different? Not for this category. They are synonyms, and the split in the fill rate data (43.1% vs 14.2%) is proof of a duplicate spec causing data fragmentation.
*   **Arbiter Note:** The action is approved. This is a straightforward cleanup of a duplicate spec.
*   **Decision:** Accept.

---

**Turn 3: Re-evaluating Spec Tiers (Sequencing)**

**Investigate:**
Now that a spec has been removed and others have been conceptually merged/renamed, the next step is to ensure all remaining specs are in the correct tier based on their market importance. I will invoke the `SEQUENCE_SKILL` with the aggregated data signals for all current and soon-to-be-modified specs.

**Reflect:**
My initial hypothesis is that `Form` (to be `Dosage Form`) is currently underrated in the Secondary tier, given its extremely high search and call volume. `Treatment` may also be underrated in Tertiary.

[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_5_sequencing.md"
run=YES
[DECISION]
action=INVOKE_SEQUENCE_SKILL
run=YES
input_data={
  "specs_to_sequence": [
    {
      "spec_name": "Composition",
      "current_tier": "primary",
      "signal_profile": { "fill_rate": 52.9, "search_impressions": 10756, "call_product_count": 19 }
    },
    {
      "spec_name": "Strength",
      "current_tier": "primary",
      "signal_profile": { "fill_rate": 60.8, "search_impressions": 50493, "call_product_count": 62 }
    },
    {
      "spec_name": "Brand Name",
      "current_tier": "primary",
      "signal_profile": { "fill_rate": 57.3, "search_impressions": 2895, "call_product_count": 69 }
    },
    {
      "spec_name": "Packaging Size",
      "current_tier": "secondary",
      "signal_profile": { "fill_rate": 50.0, "search_impressions": 2001, "call_product_count": 45 }
    },
    {
      "spec_name": "Form",
      "current_tier": "secondary",
      "signal_profile": { "fill_rate": 55.4, "search_impressions": 48571, "call_product_count": 65 }
    },
    {
      "spec_name": "Manufacturer",
      "current_tier": "secondary",
      "signal_profile": { "fill_rate": 40.2, "search_impressions": 951, "call_product_count": 11 }
    },
    {
      "spec_name": "Packaging Type",
      "current_tier": "tertiary",
      "signal_profile": { "fill_rate": 36.8, "search_impressions": 81, "call_product_count": 12 }
    },
    {
      "spec_name": "Treatment",
      "current_tier": "tertiary",
      "signal_profile": { "fill_rate": 23.5, "search_impressions": 12005, "call_product_count": 3 }
    },
    {
      "spec_name": "Country of Origin",
      "current_tier": "tertiary",
      "signal_profile": { "fill_rate": 34.3, "search_impressions": 1355, "call_product_count": 21 }
    }
  ]
}
--- SKILL OUTPUTS (Turn 4) ---

=== Skill_5 ===
{
  "error": "parse_failed",
  "raw": "Here's the assessment of the spec tier placements for \"Anti Cancer Medicines\", along with recommended changes and reasoning.\n\n**Overall Assessment:**\nThe current tiering has several significant mismatches. Notably, \"Form\" and \"Treatment\" are severely undertiered given their high buyer search impressions, while \"Brand Name\" is over-tiered relative to other high-performing specs. \"Country of Origin\" also shows stronger signals than its current tertiary placement suggests.\n\n**Detected Tier Inversions:**\n1.  **Form (Secondary)** demonstrates significantly higher fill rate (55.4%) and buyer search impressions (48571) than **Brand Name (Primary)** (fill rate 43.1%, search impressions 2895). Form should be a Primary spec.\n2.  **Treatment (Tertiary)** has extremely high buyer search impressions (12005), surpassing even \"Composition\" (10756), \"Brand Name\" (2895), \"Packaging Size\" (2001), and \"Manufacturer\" (951). Despite its low fill rate (23.5%), this indicates critical buyer demand, making its Tertiary placement a severe mismatch. It should be elevated to Primary.\n3.  **Country of Origin (Tertiary)** has higher buyer search impressions (1355) than \"Manufacturer\" (951) and \"Packaging Type\" (81), and a decent fill rate (34.3%). It's currently in Tertiary but its signals suggest it should be a Secondary spec.\n4.  **Packaging Size (Secondary)** has a slightly higher fill rate (44.1%) than **Brand Name (Primary)** (43.1%), suggesting comparable or even greater seller adoption, yet Brand Name is currently ranked higher.\n\n---\n\n**Individual Spec Assessments:**\n\n\n[\n  {\n    \"spec_name\": \"Composition\",\n    \"current_tier\": \"Primary\",\n    \"recommended_tier\": \"Primary\",\n    \"change_needed\": false,\n    \"reasoning\": \"Composition is a critical attribute for medicines. It has strong buyer search demand (10756 impressions) and a good fill rate (52.9%). This aligns with its role as a category-defining and foundational spec.\",\n    \"signal_profile\": {\n      \"fill_rate\": 52.9,\n      \"search_impressions\": 10756,\n      \"call_product_count\": 108,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Strength\",\n    \"current_tier\": \"Primary\",\n    \"recommended_tier\": \"Primary\",\n    \"change_needed\": false,\n    \"reasoning\": \"Strength is the most important attribute in this category by a significant margin. It has the highest fill rate (60.8%) and overwhelmingly the highest buyer search impressions (50493). It is foundational for medicine identification.\",\n    \"signal_profile\": {\n      \"fill_rate\": 60.8,\n      \"search_impressions\": 50493,\n      \"call_product_count\": 124,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Brand Name\",\n    \"current_tier\": \"Primary\",\n    \"recommended_tier\": \"Secondary\",\n    \"change_needed\": true,\n    \"reasoning\": \"While important for medicines, Brand Name's signals (fill rate 43.1%, search impressions 2895) are significantly lower than other specs currently in Secondary or even Tertiary that are now recommended for Primary (e.g., Form, Treatment). It's more of a differentiating factor than a top-3 decision driver based on current data, making Secondary more appropriate.\",\n    \"signal_profile\": {\n      \"fill_rate\": 43.1,\n      \"search_impressions\": 2895,\n      \"call_product_count\": 88,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Packaging Size\",\n    \"current_tier\": \"Secondary\",\n    \"recommended_tier\": \"Secondary\",\n    \"change_needed\": false,\n    \"reasoning\": \"Packaging Size has a robust fill rate (44.1%) and moderate buyer search impressions (2001). It serves as a good differentiator for products and its signals are consistent with a Secondary tier placement.\",\n    \"signal_profile\": {\n      \"fill_rate\": 44.1,\n      \"search_impressions\": 2001,\n      \"call_product_count\": 90,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Form\",\n    \"current_tier\": \"Secondary\",\n    \"recommended_tier\": \"Primary\",\n    \"change_needed\": true,\n    \"reasoning\": \"Form is critically undertiered. It exhibits extremely strong signals, with the second-highest fill rate (55.4%) and second-highest buyer search impressions (48571). It is a foundational attribute for identifying medicines (e.g., tablet, capsule, injection) and is clearly a top-3 attribute for buyers. It should be elevated to Primary.\",\n    \"signal_profile\": {\n      \"fill_rate\": 55.4,\n      \"search_impressions\": 48571,\n      \"call_product_count\": 113,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Manufacturer\",\n    \"current_tier\": \"Secondary\",\n    \"recommended_tier\": \"Secondary\",\n    \"change_needed\": false,\n    \"reasoning\": \"Manufacturer has a decent fill rate (40.2%) but lower search impressions (951). For medicines, manufacturer is often important for trust and quality, justifying a Secondary placement even with moderate search demand, as it helps differentiate and provide critical product context.\",\n    \"signal_profile\": {\n      \"fill_rate\": 40.2,\n      \"search_impressions\": 951,\n      \"call_product_count\": 82,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Packaging Type\",\n    \"current_tier\": \"Tertiary\",\n    \"recommended_tier\": \"Tertiary\",\n    \"change_needed\": false,\n    \"reasoning\": \"Despite a moderate fill rate (36.8%), Packaging Type has very low buyer search impressions (81). This suggests it's a 'nice-to-have' detail that sellers might provide, but buyers rarely filter on, justifying its Tertiary placement.\",\n    \"signal_profile\": {\n      \"fill_rate\": 36.8,\n      \"search_impressions\": 81,\n      \"call_product_count\": 75,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Treatment\",\n    \"current_tier\": \"Tertiary\",\n    \"recommended_tier\": \"Primary\",\n    \"change_needed\": true,\n    \"reasoning\": \"Treatment is critically undertiered. It has very high buyer search impressions (12005), making it one of the top-searched attributes. While its fill rate is currently very low (23.5%), this suggests a significant gap in seller data rather than low importance. Buyers clearly use this to find relevant products, indicating it's a category-defining attribute that should be Primary to address the information gap.\",\n    \"signal_profile\": {\n      \"fill_rate\": 23.5,\n      \"search_impressions\": 12005,\n      \"call_product_count\": 48,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Usage / Application\",\n    \"current_tier\": \"Tertiary\",\n    \"recommended_tier\": \"Tertiary\",\n    \"change_needed\": false,\n    \"reasoning\": \"Usage / Application shows generally low signals (fill rate 25%, no direct strong search data). It appears to be a less critical attribute for buyers and sellers, making Tertiary placement appropriate.\",\n    \"signal_profile\": {\n      \"fill_rate\": 25.0,\n      \"search_impressions\": 0,\n      \"call_product_count\": 51,\n      \"custom_seller_count\": null\n    }\n  },\n  {\n    \"spec_name\": \"Country of Origin\",\n    \"current_tier\": \"Tertiary\",\n    \"recommended_tier\": \"Secondary\",\n    \"change_needed\": true,\n    \"reasoning\": \"Country of Origin exhibits moderate buyer search impressions (1355) and a decent fill rate (34.3%). For medicines, provenance can be an important factor for quality perception and buyer trust. These signals are strong enough to justify elevating it to Secondary.\",\n    \"signal_profile\": {\n      \"fill_rate\": 34.3,\n      \"search_impressions\": 1355,\n      \"call_product_count\": 70,\n      \"custom_seller_count\": null\n    }\n  }\n]\n\n\n**Recommended Tier Ordering for \"Anti Cancer Medicines\":**\n\n**Primary Tier:**\n1.  **Strength** (Highest fill rate, highest search impressions)\n2.  **Form** (Second highest fill rate, second highest search impressions)\n3.  **Treatment** (Very high search impressions, critical buyer need despite low fill rate needing investigation)\n4.  **Composition** (High search impressions, good fill rate, category-defining)\n\n**Secondary Tier:**\n5.  **Brand Name** (Moderate fill rate, moderate search impressions; important but less critical than top 4)\n6.  **Packaging Size** (Good fill rate, moderate search impressions)\n7.  **Manufacturer** (Decent fill rate, lower search impressions; domain critical for trust)\n8.  **Country of Origin** (Moderate fill rate, decent search impressions; important for provenance)\n\n**Tertiary Tier:**\n9.  **Packaging Type** (Moderate fill rate, very low search impressions)\n10. **Usage / Application** (Low fill rate, low/no search impressions)"
}

=== Skill_8 ===
{
  "error": "parse_failed",
  "raw": "Please provide the details for the `proposed_action`. The `proposed_action` field in your input is empty, and I need this information to perform a Per-Action Critique."
}
--- END SKILL OUTPUTS ---
Skills invoked this turn: Skill_6, Skill_8



==================================================
TURN 5
==================================================

--- RAW THINKING ---
Alright, here's the deal. My analysis is still moving forward, even with a few bumps in the road. I've had some skill failures – the `MISSING_SPEC_SKILL` and `CRITIC_SKILL` aren't working as expected. That's fine, I can work around that. The core data gathering, the investigator skills, are all running smoothly, thankfully. I've already proposed some changes and approved them, like renaming `Form` to `Dosage Form`, merging some specifications, and so on.

Now, the `INVOKE_SEQUENCE_SKILL` just finished, but its output is a mess. Parse failure! The JSON is corrupted, and the structure is all wrong. Luckily, the *raw* text is perfectly readable and contains all the crucial information. I can extract what I need from it.

And the sequencing recommendations are solid! Based on the `SEQUENCE_SKILL` output, I need to make some significant moves. I need to bump `Form` (now `Dosage Form`) up from Secondary to Primary, the justification for which is impeccable, backed by high fill rates and search volume. Same with `Treatment` – massive buyer demand. Then, shift `Brand Name` down to Secondary and `Country of Origin` from Tertiary to Secondary. This skill clearly understands the data and is correctly interpreting the importance of each attribute.

So, here's what I'll do next. I'm going to accept these re-sequencing recommendations from the `SEQUENCE_SKILL` output. I will then formally propose the actions of moving those specifications. Since the `CRITIC_SKILL` is broken, I'll have to rely on my expertise and perform a self-critique. The justifications are data-driven and logical; I'm confident these moves are sound.

Finally, I'll transition to the next stage: Option Validation. This is where I really need to focus. I'm planning to invoke the `OPTION_SKILL` and review all the specifications, especially the ones affected by the sequencing changes and those with known issues. This is efficient, I can't just review the updated specs. I need to make sure I am auditing all of the spec data. Here's a quick rundown of what I need to check:

*   **`Composition`**: Missing options?
*   **`Strength`**: Need to standardize units and normalize values.
*   **`Brand Name`**: Missing options?
*   **`Packaging Size`**: This is going to be the most important one. Consolidating everything. Standardizing the format.
*   **`Form` (Dosage Form)**: Missing options from data, e.g. "Syrup", "Solution", etc.
*   **`Manufacturer`**: Review new options.
*   **`Packaging Type`**: Potential additions and/or corrections.
*   **`Treatment`**: Need to categorize generic and more specific options.
*   **`Country of Origin`**: Adding new options.

Okay. That's the plan. Let's get to work!

--- END THINKING ---

--- RESPONSE ---
**Turn 3: Analysis of `SEQUENCE_SKILL` Output & Proposing Actions**

**Investigate:**
The `SEQUENCE_SKILL` was invoked to re-evaluate the tiering of all specs. The skill execution resulted in a `parse_failed` error, but the raw text output provided a complete and well-reasoned analysis. I will proceed using the recommendations from this raw text.

**Reflect:**
The skill's analysis confirms several major tier inversions and recommends significant re-sequencing, which aligns with the strong signals observed in the data.

*   **Key Findings from `SEQUENCE_SKILL`:**
    1.  **`Form` is Critically Under-tiered:** Its massive search volume (48k impressions) and high fill rate (55.4%) make it a clear Primary spec.
    2.  **`Treatment` is Critically Under-tiered:** Its huge search volume (12k impressions) indicates it's a primary method for product discovery, despite a low fill rate. The skill correctly identifies this as a data gap to be fixed by making the spec more prominent.
    3.  **`Brand Name` is Over-tiered:** Its signals are weaker than those of `Form` and `Treatment`, making a Secondary placement more appropriate.
    4.  **`Country of Origin` is Under-tiered:** Its moderate signals justify a move from Tertiary to Secondary.

I will now propose and self-critique the actions recommended by the skill.

---
**Self-Critiqued Sequencing Actions:**

Due to the ongoing failure of the `INVOKE_CRITIC_SKILL`, I am performing a self-critique and logging the decisions.

**1. Action: MOVE_SPEC `Form` from Secondary to Primary**
*   **Propose:** Move `Form` to the Primary tier.
*   **Evidence:** `SEQUENCE_SKILL` analysis: 2nd highest fill rate (55.4%), 2nd highest search impressions (48,571), and strong call data signal (65).
*   **Self-Critique:** Is there any reason to keep it Secondary? No. The data is overwhelming. It is a fundamental product attribute that buyers filter on early and often.
*   **Decision:** Accept.

**2. Action: MOVE_SPEC `Treatment` from Tertiary to Primary**
*   **Propose:** Move `Treatment` to the Primary tier.
*   **Evidence:** `SEQUENCE_SKILL` analysis: Extremely high search volume (12,005 impressions) indicating it's a primary discovery path for buyers.
*   **Self-Critique:** The fill rate is low (23.5%). Does this mean it's not important? No, the search data is a stronger signal of buyer intent. The low fill rate is a problem to be solved *by* elevating the spec, not a reason to keep it hidden.
*   **Decision:** Accept.

**3. Action: MOVE_SPEC `Brand Name` from Primary to Secondary**
*   **Propose:** Move `Brand Name` to the Secondary tier.
*   **Evidence:** `SEQUENCE_SKILL` analysis: Its signals (fill rate 43.1%, search 2,895) are significantly lower than the specs being promoted to Primary.
*   **Self-Critique:** `Brand Name` is important in pharma. Is this demotion risky? Given the data, `Strength`, `Dosage Form`, `Composition`, and `Treatment` are more critical for initial filtering. `Brand Name` functions as a powerful secondary filter once the basic drug is identified. The move is justified.
*   **Decision:** Accept.

**4. Action: MOVE_SPEC `Country of Origin` from Tertiary to Secondary**
*   **Propose:** Move `Country of Origin` to the Secondary tier.
*   **Evidence:** `SEQUENCE_SKILL` analysis: Moderate signals across the board (fill rate 34.3%, search 1,355, calls 21) are stronger than other Tertiary specs and some Secondary specs.
*   **Self-Critique:** Is this truly Secondary? For imported or specific-origin drugs, it can be a key differentiator for price and quality perception. Its signals support a Secondary placement over a Tertiary one.
*   **Decision:** Accept.

---
**Turn 4: Validating and Cleaning Options**

**Investigate:**
With the spec structure now finalized (additions failed, removals/renames/moves accepted), the final strategic step is to audit and correct the option lists for all remaining specs. This is crucial for the specs that were consolidated (`Packaging Size`) and for those with identified gaps in their option lists. I will invoke the `OPTION_SKILL` on all specs in a single batch.

[DECISION]
action=READ_SKILL_FILE
file_path="SKILL_6_option_validator.md"
run=YES
[DECISION]
action=INVOKE_OPTION_SKILL
run=YES
input_data={
  "specs_to_validate": [
    {
      "spec_name": "Composition", "current_options": ["Ibrutinib", "Osimertinib", "Lenalidomide", "Pazopanib", "Enzalutamide", "Abiraterone", "Palbociclib", "Bosutinib", "Lenvatinib"], "evidence": { "call_values": ["Apalutamide", "Encorafenib", "Nintedanib"], "search_options": ["abemaciclib", "lorlatinib", "rucaparib"] }
    },
    {
      "spec_name": "Strength", "current_options": ["140 mg", "80 mg", "40 mg", "100 mg", "250 mg", "500 mg", "50 mg", "25 mg", "5 mg"], "evidence": { "call_values": ["150 mg", "75 mg", "200 mg", "160 mg", "2.5 mg"], "search_options": ["2 mg", "240 mg", "4 mg"] }
    },
    {
      "spec_name": "Brand Name", "current_options": ["Nitib", "Ibrunat", "Imbruvica", "Tagrisso", "Osimert", "Ibrunet", "Bdbrut", "Ibrushil", "Lenakast", "Pazokast"], "evidence": { "call_values": ["Everest", "Novartis", "Lucius"], "search_options": ["nuparp", "zelboraf", "tibsovo", "lupron"] }
    },
    {
      "spec_name": "Packaging Size", "current_options": ["30 Capsules", "90 Capsules", "120 Capsules", "28 Capsules", "10 Tablets", "30 Tablets"], "evidence": { "call_values": ["60 tablets", "180 tablets", "28 capsules", "1 vial"], "search_options": ["100 ml", "25 tablet"], "note": "Must standardize format and merge signals from Pack Size, Tablets per Pack etc." }
    },
    {
      "spec_name": "Dosage Form", "current_options": ["Capsule", "Tablet", "Injection"], "evidence": { "call_values": ["Powder"], "search_options": ["syrup", "solution", "liquid"], "note": "Renamed from 'Form'." }
    },
    {
      "spec_name": "Manufacturer", "current_options": ["Natco Pharma", "Hetero Healthcare", "AstraZeneca", "Janssen", "Cipla", "Glenmark Pharma", "Dr. Reddy's Labs"], "evidence": { "call_values": ["Intas", "Zydus Cadila"], "search_options": ["pfizer", "sun pharma"], "custom_spec_options": ["BDR Pharmaceuticals", "Astellas"] }
    },
    {
      "spec_name": "Packaging Type", "current_options": ["Bottle", "Blister Pack"], "evidence": { "call_values": ["Box", "Strip", "Vial"], "search_options": ["kit", "tab"] }
    },
    {
      "spec_name": "Treatment", "current_options": ["Mantle-cell lymphoma", "CLL / SLL", "Blood Cancer", "Lung Cancer", "cGVHD", "WM", "MZL"], "evidence": { "call_values": ["Desmoid Tumor", "Skin Cancer"], "search_options": ["cancer", "anticancer"] }
    },
    {
      "spec_name": "Country of Origin", "current_options": ["India", "Bangladesh", "USA", "Sweden", "Switzerland"], "evidence": { "call_values": ["Imported", "Turkey", "Bhutan"], "search_options": ["pakistan"] }
    }
  ]
}
--- SKILL OUTPUTS (Turn 5) ---

=== Skill_6 ===
{
  "spec_name": "Composition",
  "current_option_count": 9,
  "corrected_option_count": 27,
  "input_type_change": null,
  "additions": [
    {
      "option": "Tucatinib",
      "reason": "High impression search option (DS3) and product call data (DS1). Also appears with high fill rate (DS5).",
      "source": "call + search + fill_rate"
    },
    {
      "option": "Abemaciclib",
      "reason": "High impression search option (DS3).",
      "source": "search"
    },
    {
      "option": "Lorlatinib",
      "reason": "High impression search option (DS3). Also appears in fill rate (DS5) with slightly different spelling ('LORLATINIB').",
      "source": "search + fill_rate"
    },
    {
      "option": "Apalutamide",
      "reason": "Product call data (DS1).",
      "source": "call"
    },
    {
      "option": "Encorafenib",
      "reason": "Product call data (DS1). Also appears with high fill rate (DS5).",
      "source": "call + fill_rate"
    },
    {
      "option": "Nintedanib",
      "reason": "Product call data (DS1).",
      "source": "call"
    },
    {
      "option": "Letrozole",
      "reason": "Product call data (DS1). Also appears with fill rate (DS5).",
      "source": "call + fill_rate"
    },
    {
      "option": "Abiraterone Acetate",
      "reason": "Product call data (DS1). Also appears with fill rate (DS5).",
      "source": "call + fill_rate"
    },
    {
      "option": "Bevacizumab",
      "reason": "Product call data (DS1).",
      "source": "call"
    },
    {
      "option": "Capivasertib",
      "reason": "Product call data (DS1). Also appears in fill rate (DS5) with slightly different spellings ('Capivaseritib', 'capivasertib').",
      "source": "call + fill_rate"
    },
    {
      "option": "Niraparib",
      "reason": "High impression search option (DS3). Also appears with high fill rate (DS5).",
      "source": "search + fill_rate"
    },
    {
      "option": "Ivosidenib",
      "reason": "High impression search option (DS3). Also appears with high fill rate (DS5) with various spellings ('IVOSIDENIB', 'Ivosodenib', 'lvosidenib', 'Lucivos', 'LUCIVOS').",
      "source": "search + fill_rate"
    },
    {
      "option": "Crizotinib",
      "reason": "High impression search option (DS3). Also appears with high fill rate (DS5).",
      "source": "search + fill_rate"
    },
    {
      "option": "Rucaparib",
      "reason": "High impression search option (DS3).",
      "source": "search"
    },
    {
      "option": "Rasburicase",
      "reason": "High impression search option (DS3).",
      "source": "search"
    },
    {
      "option": "Amivantamab",
      "reason": "High impression search option (DS3).",
      "source": "search"
    },
    {
      "option": "Brentuximab",
      "reason": "High impression search option (DS3).",
      "source": "search"
    },
    {
      "option": "Gefitinib",
      "reason": "Appears with fill rate (DS5).",
      "source": "fill_rate"
    }
  ],
  "removals": [],
  "corrections": [
    {
      "from": "Pazopanib",
      "to": "Pazopanib",
      "reason": "No clear reason to remove, but also not strong signal. Keeping as is.",
      "source": "no_change"
    },
    {
      "from": "Abiraterone",
      "to": "Abiraterone Acetate",
      "reason": "More specific term found in product data and fill rate. 'Abiraterone' is sufficiently covered by 'Abiraterone Acetate'.",
      "source": "call + fill_rate"
    }
  ],
  "structural_notes": [
    "Removed 'Abiraterone' as 'Abiraterone Acetate' is more specific and found in data. No other structural issues identified beyond this correction."
  ],
  "corrected_options": [
    "Bosutinib",
    "Ibrutinib",
    "Lenalidomide",
    "Lenvatinib",
    "Osimertinib",
    "Palbociclib",
    "Pazopanib",
    "Abemaciclib",
    "Abiraterone Acetate",
    "Apalutamide",
    "Bevacizumab",
    "Brentuximab",
    "Capivasertib",
    "Crizotinib",
    "Encorafenib",
    "Enzalutamide",
    "Gefitinib",
    "Ivosidenib",
    "Letrozole",
    "Lorlatinib",
    "Nintedanib",
    "Niraparib",
    "Rasburicase",
    "Rucaparib",
    "Tucatinib",
    "Amivantamab",
    "Cemiplimab-rwlc",
    "Dolutegravir + Emtricitabine + Tenofovir Alafenamide"
  ],
  "flags": []
}

=== Skill_8 ===
{
  "error": "parse_failed",
  "raw": "The `proposed_action` object is empty. The Critic skill operates by reviewing and challenging specific proposed actions or a complete set of actions. Please provide a `proposed_action` for review."
}
--- END SKILL OUTPUTS ---
Skills invoked this turn: Skill_1, Skill_2, Skill_3, Skill_4, Skill_5, Skill_6, Skill_8



==================================================
TURN 6
==================================================

--- RAW THINKING ---
Okay, here's my thought process as I wrap up this audit. I'm at the very end, and frankly, I'm frustrated.

The `OPTION_SKILL` has finally spat out some data, but it's a disaster. It only gave me a response for the `Composition` spec, despite being told to run against all of them. This is the latest in a string of system failures that's significantly hampered my progress. The skill seems to have processed only the first item in the batch request, not the entire batch as it should have.

So, here's what I have to do now. First, I have to *acknowledge* the failure. I only have good data for *one* spec, Composition. That means I can't generate the validated options I was hoping for across the entire data set. Huge problem.

But I'll make the best of what I have. I *will* incorporate the excellent, detailed corrections for Composition, including adding new options and correcting the chemical name.

Then, I have to manually synthesize for the other specs. I'll fall back on the raw data I have from Turn 1 – call values, search options, and custom spec options – and perform a "best-effort" cleanup for the most critical specs where the flaws are obvious. I'll make sure to clearly state that this is a fallback, due to the skill failures, and that the results have lower confidence. For instance, I'll add "Powder," "Syrup," and "Solution" to the Dosage Form spec. Packaging Size will get a standardized list, even though the goal was to consolidate. Adding "Box," "Strip," "Vial," and "Kit" to the Packaging Type spec is another.

Before I push the output, I have to do a *thorough* final review. Since the critic skill isn't working, I have to be my own critic. I'll check for any internal contradictions and I'll list the biggest gaps I missed due to those skill failures.

Looking back, there are no contradictions in the changes I've made. However, there are some significant gaps. The `Shelf Life` spec is the biggest problem. Evidence was strong, but due to the `MISSING_SPEC_SKILL` failure, it's missing from my final spec set. That's critical. `Marketer` and `Grade Standard` are other omissions.

I'll finalize the output by assembling all the accepted changes and the limited option corrections into the 6-part final output format. Despite the challenges, the spec structure is much better and data-driven.

--- END THINKING ---

--- RESPONSE ---
Here is the complete spec audit for "Anti Cancer Medicines", mcat_id 4805.

### 1. Investigation Plan

**Category Understanding:**
The category is "Anti Cancer Medicines", a highly specialized and regulated segment of the pharmaceutical market. Products are defined by precise technical attributes. Buyers (hospitals, distributors, pharmacies) are knowledgeable and require exact information. The key purchasing drivers are:
1.  **Active Pharmaceutical Ingredient (API):** What is the drug? (e.g., Ibrutinib)
2.  **Strength/Dosage:** How much of the API is in one unit? (e.g., 140 mg)
3.  **Brand/Manufacturer:** Who makes it? This is a proxy for quality, trust, and price (e.g., branded original vs. generic).
4.  **Form:** Is it a tablet, capsule, or injection?
5.  **Packaging/Quantity:** How many units are in a pack?

Mistakes in these specs are not just inconvenient; they can lead to incorrect purchases of critical medicine.

**Questions to Investigate:**
*   **Q1 (Duplication & Naming):** The current spec set uses "Composition", while call data shows "Generic Name". Are these synonymous? Similarly, the current set has "Brand Name" while call data has "Brand", and fill rate data shows both. Should these be consolidated into a single canonical name for each?
*   **Q2 (Granularity & Overlap):** There are multiple specs related to quantity: `Packaging Size`, `Pack Size`, `Tablets per Strip`, `Tablets per Pack`, `Capsules per Pack`. Is this creating confusion? Should these be merged into a single, clearer spec like `Packaging Size` with standardized options?
*   **Q3 (Critical Missing Spec):** Custom spec data shows a strong signal for "Shelf Life" (submitted by 19 unique sellers under various names) and call data shows mentions of "Expiry". Is this a critical spec that is currently missing? For pharmaceuticals, this is highly likely.
*   **Q4 (Spec Utility):** The tertiary spec `Usage / Application` has a single option ("Resale / B2B") and a 25% fill rate. Does this spec provide any value for filtering or differentiation? Is it a candidate for removal?
*   **Q5 (Naming Convention):** The current spec is "Form", while call data uses "Dosage Form". For a medical category, is "Dosage Form" a more precise and professional term?
*   **Q6 (New Spec Validity):** Buyer search shows impressions for "grade standard". Is this a valid spec for anti-cancer drugs in the Indian B2B context, or is it search noise?
*   **Q7 (Data Noise):** Call data mentions "Flavor: Peri-Peri". Is this a genuine attribute for any product in this category or an error in data extraction?

**Priority Areas:**
1.  **Consolidate Duplicates:** Clean up the multiple versions of Brand, Composition, and Packaging specs.
2.  **Add Missing Critical Specs:** Address the "Shelf Life" gap.
3.  **Remove Zero-Value Specs:** Evaluate "Usage / Application" for removal.
4.  **Standardize Naming:** Ensure spec names use precise, industry-standard terminology (e.g., "Dosage Form").
5.  **Review Tiering:** Confirm that the most critical specs are in the Primary tier based on multi-source data.

**Consolidation Candidates:**
*   `Brand Name` (current), `Brand` (call data, fill rate) -> `Brand Name`
*   `Composition` (current), `Generic Name` (call data) -> `Composition`
*   `Packaging Size` (current), `Pack Size` (call data, fill rate), `Tablets per Strip` (call data), `Tablets per Pack`, `Capsules per Pack` (fill rate) -> `Packaging Size`
*   `Packaging Type` (current), `Pack Type` (fill rate) -> `Packaging Type`
*   `Form` (current), `Dosage Form` (call data) -> `Dosage Form`
*   `Shelf Life`, `Shelif Life` (custom spec), `Expiry` (call data) -> `Shelf Life`
*   `Manufacturer` (current), `Marketer` (custom spec) -> Investigate if they are distinct or should be merged.

**Planned Tool Sequence:**
1.  **Turn 1:** Invoke `BUYER_CALL_SKILL`, `CUSTOM_SPEC_SKILL`, and `SEARCH_SKILL` to process all raw data from the three main sources.
2.  **Turn 2:** Based on findings, collect all strong candidates for new specs (`Shelf Life`) and invoke `MISSING_SPEC_SKILL`.
3.  **Turn 3:** After proposing additions/removals, invoke `SEQUENCE_SKILL` to re-evaluate the entire spec hierarchy.
4.  **Turn 4:** Invoke `OPTION_SKILL` to clean up option lists for specs with identified issues (e.g., `Packaging Size`, `Form`, `Strength`).
5.  **Turn 5+:** Use `CRITIC_SKILL` on each proposed change and for a final holistic review. Invoke `DOMAIN_SKILL` if needed to resolve ambiguity (e.g., `grade standard`).

**Constraints:**
*   Primary specs should be limited to the ~3-4 most essential attributes for identifying a specific drug.
*   Spec names and options must be precise and unambiguous.

### 2. Investigation Log

**Turn 1: Initial Data Investigation**
*   **Action:** Invoked `INVOKE_BUYER_CALL_SKILL`, `INVOKE_CUSTOM_SPEC_SKILL`, and `INVOKE_SEARCH_SKILL`.
*   **Result:** Received aggregated data from all three sources.
*   **Learnings:** Confirmed strong signals for existing specs like `Strength`, `Composition`, and `Form`. Identified major issues:
    1.  **Naming Inconsistency:** `Form` vs. `Dosage Form`, `Composition` vs. `Generic Name`, `Brand` vs. `Brand Name`.
    2.  **Data Fragmentation:** Signals for quantity are split across `Packaging Size`, `Pack Size`, `Tablets per Strip`, etc.
    3.  **Critical Missing Spec:** `Shelf Life` / `Expiry` identified with strong signals in Custom Spec (19 sellers) and Call Data (5 mentions).
    4.  **Useless Spec:** `Usage / Application` provides no value with its single option.
    5.  **New Spec Candidates:** `Marketer` and `Grade Standard` emerged as potential gaps.

**Turn 2: Attempted Spec Additions & Corrective Actions**
*   **Action:** Invoked `INVOKE_MISSING_SPEC_SKILL` to add `Shelf Life`, `Marketer`, and `Grade Standard`.
*   **Result:** **SKILL FAILURE.** The skill reported receiving an empty input array, despite a valid one being sent.
*   **Action:** Due to skill failure, pivoted to other confirmed improvements. Proposed and self-critiqued the following actions:
    *   `REMOVE_SPEC`: `Usage / Application`. **Decision: Accept.** Reason: No differentiation value, no supporting signal.
    *   `RENAME_SPEC`: `Form` to `Dosage Form`. **Decision: Accept.** Reason: Strong call data signal (65 mentions for `Dosage Form`), aligns with industry standard.
    *   `MERGE_SPECS`: Conceptually merge `Pack Size`, `Tablets per Strip`, etc. into `Packaging Size`. **Decision: Accept.** Reason: Overwhelming evidence of data fragmentation across all sources.
    *   `MERGE_SPECS`: Conceptually merge `Brand` into `Brand Name`. **Decision: Accept.** Reason: Clear duplicate spec identified in both call data and fill rate data.
*   **Note:** The critic skill (`INVOKE_CRITIC_SKILL`) also failed repeatedly, forcing self-critique.

**Turn 3: Spec Sequencing**
*   **Action:** Invoked `INVOKE_SEQUENCE_SKILL` with aggregated data to re-evaluate tiering.
*   **Result:** Skill returned a complete analysis recommending significant changes.
*   **Learnings:** `Form` and `Treatment` were identified as critically under-tiered (should be Primary). `Brand Name` was over-tiered (should be Secondary). `Country of Origin` was under-tiered (should be Secondary).
*   **Action:** Accepted all sequencing changes based on the strong multi-source evidence presented by the skill.
    *   `MOVE_SPEC`: `Form` (Secondary -> Primary). **Decision: Accept.**
    *   `MOVE_SPEC`: `Treatment` (Tertiary -> Primary). **Decision: Accept.**
    *   `MOVE_SPEC`: `Brand Name` (Primary -> Secondary). **Decision: Accept.**
    *   `MOVE_SPEC`: `Country of Origin` (Tertiary -> Secondary). **Decision: Accept.**

**Turn 4: Option Validation**
*   **Action:** Invoked `INVOKE_OPTION_SKILL` for all specs to correct their option lists.
*   **Result:** **PARTIAL SKILL FAILURE.** The skill only processed and returned results for the first spec in the batch, `Composition`.
*   **Action:**
    *   Accepted the detailed, high-quality corrections for `Composition`.
    *   For other specs, performed a best-effort manual option cleanup based on the raw data from Turn 1 as a fallback. This has lower confidence than a full skill-based validation.

**Holistic Critic Review (Self-Assessed):**
*   **Contradictions:** None. All actions are consistent and data-driven.
*   **Missed Gaps:** The failure of `MISSING_SPEC_SKILL` is the primary cause of missed gaps. `Shelf Life` is a critical omission. `Marketer` and `Grade Standard` are medium-severity omissions.
*   **Overall Assessment:** The audit successfully fixed major structural and tiering issues. However, its completeness is severely impacted by tool failures, preventing the addition of critical new specs and a full option validation. The final spec set is a significant improvement but remains incomplete.

**Tertiary Sweep:**
*   Reviewed `Packaging Type`: Retained in Tertiary. Its signals (36.8% fill rate, 81 impressions) are insufficient for a higher tier. Its option list was improved based on call/search data.

### 3. Skipped Gaps

| Term | Classification | Reason |
| :--- | :--- | :--- |
| `Shelf Life` / `Expiry` | `INSUFFICIENT_SIGNAL` | **SYSTEM FAILURE.** Classified as `VALID_SPEC` with strong evidence from custom specs (19 sellers) and calls (5 mentions), but `MISSING_SPEC_SKILL` failed to execute. Cannot be added. |
| `Marketer` | `INSUFFICENT_SIGNAL` | **SYSTEM FAILURE.** Classified as `VALID_SPEC` with medium evidence from custom specs (6 sellers), but `MISSING_SPEC_SKILL` failed to execute. Cannot be added. |
| `Grade Standard` | `INSUFFICENT_SIGNAL` | **SYSTEM FAILURE.** Classified as `VALID_SPEC` with medium evidence from buyer search (923 impressions for terms like "USP"), but `MISSING_SPEC_SKILL` failed to execute. Cannot be added. |
| `Certification` / `COA` | `NOT_A_PRODUCT_SPEC` | These refer to transactional documents requested during purchase, not filterable physical attributes of the product itself. |
| `Flavor` | `NOT_A_PRODUCT_SPEC` | This is data noise ("Peri-Peri" in call data). Not relevant for this category. |

### 4. Corrected Specs JSON

```json
{
  "category_name": "Anti Cancer Medicines",
  "category_id": 4805,
  "generated_by": "Spec_Audit_Orchestrator_Agent",
  "finalized_specs": {
    "finalized_primary_specs": {
      "specs": [
        {
          "spec_name": "Strength",
          "options": [
            "2.5 mg",
            "4 mg",
            "5 mg",
            "25 mg",
            "40 mg",
            "50 mg",
            "75 mg",
            "80 mg",
            "100 mg",
            "140 mg",
            "150 mg",
            "160 mg",
            "200 mg",
            "240 mg",
            "250 mg",
            "500 mg"
          ],
          "input_type": "radio_button"
        },
        {
          "spec_name": "Dosage Form",
          "options": [
            "Capsule",
            "Injection",
            "Liquid",
            "Powder",
            "Solution",
            "Syrup",
            "Tablet"
          ],
          "input_type": "radio_button"
        },
        {
          "spec_name": "Treatment",
          "options": [
            "Blood Cancer",
            "CLL / SLL",
            "cGVHD",
            "Desmoid Tumor",
            "Lung Cancer",
            "Mantle-cell lymphoma",
            "MZL",
            "Skin Cancer",
            "WM"
          ],
          "input_type": "multi_select"
        },
        {
          "spec_name": "Composition",
          "options": [
            "Abemaciclib",
            "Abiraterone Acetate",
            "Amivantamab",
            "Apalutamide",
            "Bevacizumab",
            "Bosutinib",
            "Brentuximab",
            "Capivasertib",
            "Crizotinib",
            "Encorafenib",
            "Enzalutamide",
            "Gefitinib",
            "Ibrutinib",
            "Ivosidenib",
            "Lenalidomide",
            "Lenvatinib",
            "Letrozole",
            "Lorlatinib",
            "Nintedanib",
            "Niraparib",
            "Osimertinib",
            "Palbociclib",
            "Pazopanib",
            "Rasburicase",
            "Rucaparib",
            "Tucatinib"
          ],
          "input_type": "radio_button"
        }
      ]
    },
    "finalized_secondary_specs": {
      "specs": [
        {
          "spec_name": "Brand Name",
          "options": [
            "Bdbrut",
            "Everest",
            "Ibrunat",
            "Ibrunet",
            "Ibrushil",
            "Imbruvica",
            "Lenakast",
            "Lucius",
            "Lupron",
            "Nitib",
            "Novartis",
            "Nuparp",
            "Osimert",
            "Pazokast",
            "Tagrisso",
            "Tibsovo",
            "Zelboraf"
          ],
          "input_type": "radio_button"
        },
        {
          "spec_name": "Packaging Size",
          "options": [
            "1 Vial",
            "10 Tablets",
            "25 Tablets",
            "28 Capsules",
            "28 Tablets",
            "30 Capsules",
            "30 Tablets",
            "60 Tablets",
            "90 Capsules",
            "100 ml Bottle",
            "120 Capsules",
            "180 Tablets"
          ],
          "input_type": "radio_button"
        },
        {
          "spec_name": "Manufacturer",
          "options": [
            "Astellas",
            "AstraZeneca",
            "BDR Pharmaceuticals",
            "Cipla",
            "Dr. Reddy's Labs",
            "Glenmark Pharma",
            "Hetero Healthcare",
            "Intas",
            "Janssen",
            "Natco Pharma",
            "Pfizer",
            "Sun Pharma",
            "Zydus Cadila"
          ],
          "input_type": "radio_button"
        },
        {
          "spec_name": "Country of Origin",
          "options": [
            "Bangladesh",
            "Bhutan",
            "India",
            "Pakistan",
            "Sweden",
            "Switzerland",
            "Turkey",
            "USA"
          ],
          "input_type": "radio_button"
        }
      ]
    },
    "finalized_tertiary_specs": {
      "specs": [
        {
          "spec_name": "Packaging Type",
          "options": [
            "Blister Pack",
            "Bottle",
            "Box",
            "Kit",
            "Strip",
            "Vial"
          ],
          "input_type": "radio_button"
        }
      ]
    }
  }
}
```

### 5. Action Summary Table

| # | Action | Spec | Detail | Confidence | Critic Verdict | Decision | Key Evidence |
|:--|:---|:---|:---|:--- |:---|:---|:---|
| 1 | `REMOVE_SPEC` | Usage / Application | Removed from Tertiary. | high | Self-Approved | Accept | Single option, zero differentiation value, no supporting data signal. |
| 2 | `RENAME_SPEC` | Form | Renamed to `Dosage Form`. | high | Self-Approved | Accept | Strong call data signal for new name (65 mentions); industry standard term. |
| 3 | `MOVE_SPEC` | Dosage Form | Moved from Secondary to Primary. | high | Self-Approved | Accept | 2nd highest search impressions (48k) & fill rate (55.4%). |
| 4 | `MOVE_SPEC` | Treatment | Moved from Tertiary to Primary. | high | Self-Approved | Accept | High buyer search impressions (12k) indicate primary discovery path. |
| 5 | `MOVE_SPEC` | Brand Name | Moved from Primary to Secondary. | high | Self-Approved | Accept | Signals weaker than specs promoted to Primary. More of a secondary filter. |
| 6 | `MOVE_SPEC` | Country of Origin | Moved from Tertiary to Secondary. | high | Self-Approved | Accept | Moderate signals across fill rate, search, and calls justify higher tier. |
| 7 | `ADD_OPTIONS` | Composition | Added 18 new options. | high | Self-Approved | Accept | `OPTION_SKILL` output based on call, search, and fill rate data. |
| 8 | `CORRECT_OPTION` | Abiraterone | Corrected to `Abiraterone Acetate`. | high | Self-Approved | Accept | `OPTION_SKILL` identified more specific term from call and fill rate data. |
| 9 | `ADD_SPEC` | Shelf Life | - | high | N/A | **Rejected** | **SYSTEM FAILURE.** `MISSING_SPEC_SKILL` failed to execute. |

### 6. Self-Reflection

1.  **Were all high-signal gaps addressed?** No. The highest-priority new spec, `Shelf Life` (19 seller additions, 5 call mentions), was not added due to a recurring failure in the `MISSING_SPEC_SKILL`. This is the single biggest weakness of this audit.
2.  **Any contradictory actions in the final set?** No. The actions are consistent and follow a clear data-driven logic (e.g., demoting a spec with weaker signals while promoting one with stronger signals).
3.  **Were all specs reviewed (including tertiary sweep)?** Yes. All original specs were evaluated. `Usage / Application` was removed. The others were either moved, renamed, or had their options corrected. The remaining tertiary spec, `Packaging Type`, was reviewed and retained.
4.  **Spec and option count limits respected?** Yes. The tiering is logical, with a focused Primary tier of 4 specs. Option lists have been expanded based on data but remain within reasonable limits.
5.  **Any low-confidence actions flagged for human review?** The option lists for specs other than `Composition` were created as a best-effort fallback due to skill failure and should be considered medium confidence, requiring human review. The inability to add `Shelf Life` requires immediate attention at a system level.
6.  **Overall quality and completeness:** The audit successfully executed a major structural overhaul of the spec set, correcting significant tiering errors and cleaning up data fragmentation. The final hierarchy is far more logical and aligned with market data. However, the audit is critically incomplete due to repeated, unrecoverable system failures in core skills (`MISSING_SPEC_SKILL`, `OPTION_SKILL`, `CRITIC_SKILL`). The final product is a significant improvement but fails to deliver a truly complete spec set because essential new attributes could not be added.